Resiniferatoxin
- Generic Name
- Resiniferatoxin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C37H40O9
- CAS Number
- 57444-62-9
- Unique Ingredient Identifier
- A5O6P1UL4I
- Background
Resiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission of physiological pain).
- Indication
Investigated for use/treatment in interstitial cystitis and urinary incontinence.
- Associated Conditions
- -
- Associated Therapies
- -
First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Grünenthal enrolls first participants in Phase I trial for NOP receptor agonist, aiming to demonstrate safety and pharmacokinetic characteristics. The trial targets chronic pain relief with improved safety profile compared to opioids.
Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer
Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee. The non-opioid therapy is in Phase III development.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath